0000950170-24-076916.txt : 20240624 0000950170-24-076916.hdr.sgml : 20240624 20240624173503 ACCESSION NUMBER: 0000950170-24-076916 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240620 FILED AS OF DATE: 20240624 DATE AS OF CHANGE: 20240624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bruno Julianne CENTRAL INDEX KEY: 0002019645 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 241065505 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS STREET 2: 105 WEST FIRST STREET CITY: BOSTON STATE: MA ZIP: 02127 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 ownership.xml 4 X0508 4 2024-06-20 0001674416 CRISPR Therapeutics AG CRSP 0002019645 Bruno Julianne C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON MA 02127 false true false false Chief Operating Officer false Common Shares 2024-06-20 4 M false 7000 A 10111 D Common Shares 2024-06-21 4 S false 3366 56.09 D 6745 D Common Shares 7088 I The Julianne Bruno 2022 GRAT Restricted Stock Units 2024-06-20 4 M false 7000 D Common Shares 7000 0 D Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on December 14, 2021 with respect to 7,000 Common Shares, with 100% of the shares vesting on June 20, 2024. /s/ Elizabeth Ryland Waldinger, attorney-in-fact 2024-06-24